{"protocolSection": {"identificationModule": {"nctId": "NCT02075125", "orgStudyIdInfo": {"id": "PANTASTIC"}, "organization": {"fullName": "Dong-A University", "class": "OTHER"}, "briefTitle": "Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction", "officialTitle": "Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "TERMINATED", "whyStopped": "Enrolling participants has halted prematurely and will not resume", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-01"}, "primaryCompletionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-20", "studyFirstSubmitQcDate": "2014-02-26", "studyFirstPostDateStruct": {"date": "2014-03-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-09-13", "resultsFirstSubmitQcDate": "2015-12-24", "resultsFirstPostDateStruct": {"date": "2016-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-11", "lastUpdatePostDateStruct": {"date": "2017-08-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Moo Hyun Kim", "investigatorTitle": "M.D. Director, Global Clinical Trial Center. Professor, Dept. of Cardiology Dong-A Unicersity Hospital", "investigatorAffiliation": "Dong-A University"}, "leadSponsor": {"name": "Dong-A University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.", "detailedDescription": "Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of this study is to compare the antiplatelet efficacy and safety using laboratory platelet function tests and clinical outcomes in patients with STEMI treated with either prasugrel or ticagrelor."}, "conditionsModule": {"conditions": ["ST-Segment Elevation Myocardial Infarction"], "keywords": ["Korea", "Platelet inhibition", "Prasugrel", "Ticagrelor", "ST-segment elevation myocardial infarction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 39, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Prasugrel 60 mg", "type": "EXPERIMENTAL", "description": "Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose", "interventionNames": ["Drug: Prasugrel 60 mg"]}, {"label": "Ticagrelor 180 mg", "type": "EXPERIMENTAL", "description": "Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose", "interventionNames": ["Drug: Ticagrelor 180 mg"]}], "interventions": [{"type": "DRUG", "name": "Prasugrel 60 mg", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.", "armGroupLabels": ["Prasugrel 60 mg"], "otherNames": ["Effient 60 mg"]}, {"type": "DRUG", "name": "Ticagrelor 180 mg", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.", "armGroupLabels": ["Ticagrelor 180 mg"], "otherNames": ["Brilinta 180 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With High Platelet Reactivity", "description": "Platelet reactivity were measured by VerifyNow (volumetrics accuretic\uff0cSan Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) \\>235 and platelet reactivity index (PRI) \\>50%.", "timeFrame": "48 hours after loading dose of study drug"}], "secondaryOutcomes": [{"measure": "Major Adverse Cardiac and Cerebrovascular Events", "description": "Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30.", "timeFrame": "30 days"}, {"measure": "Bleeding Event", "description": "Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria.", "timeFrame": "30 days"}, {"measure": "Adverse Drug Reaction", "description": "Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention.", "timeFrame": "30 days"}, {"measure": "Pre-procedure P2Y12 Reaction Units (PRU)", "description": "Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU).", "timeFrame": "Baseline"}, {"measure": "Number of Participants With Low Platelet Reactivity", "description": "Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) \\<85 and platelet reactivity index (PRI)\\<16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups.", "timeFrame": "48 hours after loading dose of study drug"}, {"measure": "Pre-procedure Platelet Reactivity Index (PRI)", "description": "Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI).", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with ST-segment elevation myocardial infarction\n* Undergoing primary percutaneous coronary intervention\n* Aged between 20 and 80 years\n\nExclusion Criteria:\n\n* Previous administration of any antagonist of the platelet adenosine diphosphate (ADP) P2Y12 receptor (clopidogrel, prasugrel or ticagrelor)\n* History of stroke or transient ischemic attack\n* Previous gastrointestinal bleeding within 6 months, bleeding diathesis, platelet count \\< 100,000/mm3 or hemoglobin \\< 10 g/dl\n* Chronic oral anticoagulation treatment\n* Contraindication to the antiplatelet treatment\n* Severe renal insufficiency (serum creatine\\>2.5 mg/dl)\n* Severe hepatic dysfunction (serum liver enzyme or bilirubin\\>3 times normal limit)\n* Sever chronic obstructive pulmonary disease (COPD) or bradycardia\n* Body weight \\< 50 kg", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Moo Hyun Kim, M.D.", "affiliation": "Dong-A University Hospital, Busan, Republic of Korea", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "DongA University Hospital", "city": "Busan", "zip": "602-715", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}]}, "referencesModule": {"references": [{"pmid": "23500251", "type": "BACKGROUND", "citation": "Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6. doi: 10.1016/j.jacc.2013.01.024. Epub 2013 Mar 22."}, {"pmid": "23169985", "type": "BACKGROUND", "citation": "Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20."}, {"pmid": "25959558", "type": "DERIVED", "citation": "Lee YS, Jin CD, Kim MH, Guo LZ, Cho YR, Park K, Park JS, Park TH, Kim YD. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circ J. 2015;79(6):1248-54. doi: 10.1253/circj.CJ-15-0270. Epub 2015 May 11."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Prasugrel", "description": "Patient administer Prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "FG001", "title": "Ticagrelor", "description": "Patient administer Ticagrelor 180 mg as loading dose followed by 90 mg twice a day as maintenance dose."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "comment": "One patient switched to clopidogrel treatment after 18 days of ticagrelor treatment.", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Prasugrel", "description": "Patient administer Prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "BG001", "title": "Ticagrelor", "description": "Patients administer Ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "39"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55", "spread": "10"}, {"groupId": "BG001", "value": "55", "spread": "11"}, {"groupId": "BG002", "value": "55", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "35"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Korea, Republic of", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "39"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25.3", "spread": "2.7"}, {"groupId": "BG001", "value": "24.4", "spread": "2.4"}, {"groupId": "BG002", "value": "24.9", "spread": "2.4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With High Platelet Reactivity", "description": "Platelet reactivity were measured by VerifyNow (volumetrics accuretic\uff0cSan Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) \\>235 and platelet reactivity index (PRI) \\>50%.", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher's exact test, as appropriate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "48 hours after loading dose of study drug", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "PRU>235", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "VASP-PRI>50%", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Major Adverse Cardiac and Cerebrovascular Events", "description": "Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30.", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher's exact test, as appropriate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Bleeding Event", "description": "Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria.", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher's exact test, as appropriate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Drug Reaction", "description": "Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention.", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number, compared with chi-square statistics or Fisher's exact test, as appropriate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Pre-procedure P2Y12 Reaction Units (PRU)", "description": "Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU).", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "PRU units", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "259", "lowerLimit": "230", "upperLimit": "281"}, {"groupId": "OG001", "value": "261", "lowerLimit": "196", "upperLimit": "286"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Low Platelet Reactivity", "description": "Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) \\<85 and platelet reactivity index (PRI)\\<16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups.", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher's exact test, as appropriate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "48 hours after loading dose of study drug", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "PRU<85", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "VASP-PRI<16%", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}]}]}, {"type": "SECONDARY", "title": "Pre-procedure Platelet Reactivity Index (PRI)", "description": "Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI).", "populationDescription": "Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose."}, {"id": "OG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51.2", "lowerLimit": "39.3", "upperLimit": "61.3"}, {"groupId": "OG001", "value": "47.5", "lowerLimit": "38.4", "upperLimit": "50.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2.5", "timeFrame": "1 month", "eventGroups": [{"id": "EG000", "title": "Prasugrel", "description": "Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}, {"id": "EG001", "title": "Ticagrelor", "description": "Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 0, "otherNumAtRisk": 20}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "For the present single-center pilot study, the small sample size was a major limitation, and as such was insufficiently powered to assess safety."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Moo Hyun Kim; Director of Global Clinical Trial Center Dong-A University Hospital.", "organization": "Department of Cardiology, College of Medicine, Dong-A University.", "email": "kimmh@dau.ac.kr", "phone": "+82 (51) 240-2976"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000072657", "term": "ST Elevation Myocardial Infarction"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}], "browseLeaves": [{"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M1072", "name": "ST Elevation Myocardial Infarction", "asFound": "ST-segment Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077486", "term": "Ticagrelor"}, {"id": "D000068799", "term": "Prasugrel Hydrochloride"}], "ancestors": [{"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000058921", "term": "Purinergic P2Y Receptor Antagonists"}, {"id": "D000058919", "term": "Purinergic P2 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1812", "name": "Ticagrelor", "asFound": "Immediate", "relevance": "HIGH"}, {"id": "M310", "name": "Prasugrel Hydrochloride", "asFound": "Link", "relevance": "HIGH"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M29294", "name": "Purinergic P2Y Receptor Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}